WO2003028758A1 - Nouvelle methode d'induction de lymphocytes t specifiques d'un antigene - Google Patents

Nouvelle methode d'induction de lymphocytes t specifiques d'un antigene Download PDF

Info

Publication number
WO2003028758A1
WO2003028758A1 PCT/JP2002/009997 JP0209997W WO03028758A1 WO 2003028758 A1 WO2003028758 A1 WO 2003028758A1 JP 0209997 W JP0209997 W JP 0209997W WO 03028758 A1 WO03028758 A1 WO 03028758A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
specific
antigen
novel method
inducing antigen
Prior art date
Application number
PCT/JP2002/009997
Other languages
English (en)
French (fr)
Inventor
Haruo Sugiyama
Ichiro Azuma
Original Assignee
Haruo Sugiyama
Ichiro Azuma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haruo Sugiyama, Ichiro Azuma filed Critical Haruo Sugiyama
Priority to EP02800255A priority Critical patent/EP1447092A4/en
Priority to US10/490,865 priority patent/US20050002951A1/en
Priority to JP2003532088A priority patent/JPWO2003028758A1/ja
Publication of WO2003028758A1 publication Critical patent/WO2003028758A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001178—Tumor rejection antigen precursor [TRAP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/JP2002/009997 2001-09-28 2002-09-27 Nouvelle methode d'induction de lymphocytes t specifiques d'un antigene WO2003028758A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02800255A EP1447092A4 (en) 2001-09-28 2002-09-27 METHODS OF INDUCING ANTIGEN-SPECIFIC T CELLS
US10/490,865 US20050002951A1 (en) 2001-09-28 2002-09-27 Novel method of inducing antigen-specific t cells
JP2003532088A JPWO2003028758A1 (ja) 2001-09-28 2002-09-27 抗原特異的ｔ細胞の誘導方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-301224 2001-09-28
JP2001301224 2001-09-28

Publications (1)

Publication Number Publication Date
WO2003028758A1 true WO2003028758A1 (fr) 2003-04-10

Family

ID=19121669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/009997 WO2003028758A1 (fr) 2001-09-28 2002-09-27 Nouvelle methode d'induction de lymphocytes t specifiques d'un antigene

Country Status (4)

Country Link
US (1) US20050002951A1 (ja)
EP (1) EP1447092A4 (ja)
JP (2) JPWO2003028758A1 (ja)
WO (1) WO2003028758A1 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1371664A1 (en) * 2001-03-22 2003-12-17 Haruo Sugiyama Wti modified peptide
WO2004026897A1 (ja) 2002-09-20 2004-04-01 Chugai Seiyaku Kabushiki Kaisha Ｗｔ１置換型ペプチド
WO2005102369A1 (ja) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. 細菌細胞壁骨格成分を含有する製剤
EP1696027A1 (en) * 2003-11-05 2006-08-30 International Institute of Cancer Immunology, Inc. Hla-dr-binding antigen peptide derived from wt1
US9833493B2 (en) 2012-12-17 2017-12-05 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
US10139395B2 (en) 2007-02-27 2018-11-27 International Institute Of Cancer Immunology, Inc. Method for activation of helper T cell and composition for use in the method
WO2018219299A1 (en) * 2017-05-31 2018-12-06 Carsgen Therapeutics Co., Ltd. Compositions and methods of cellular immunotherapy
US10654892B2 (en) 2010-10-05 2020-05-19 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1178956C (zh) * 1998-07-31 2004-12-08 杉山治夫 基于癌抑制基因wt1的产物的癌抗原
EP1447091A4 (en) * 2001-09-28 2008-02-13 Institute Of Can International NEW METHOD FOR INDUCTION OF ANTIGEN SPECIFIC T CELLS
AU2003242305A1 (en) * 2002-06-12 2003-12-31 Chugai Seiyaku Kabushiki Kaisha Hla-a24-restricted cancer antigen peptide
EP1550453B1 (en) * 2002-09-12 2015-05-27 International Institute of Cancer Immunology, Inc. Cancer antigen peptide preparation
WO2004063217A1 (ja) * 2003-01-15 2004-07-29 Chugai Seiyaku Kabushiki Kaisha 二量体化ペプチド
ES2443582T3 (es) 2003-06-27 2014-02-19 International Institute Of Cancer Immunology, Inc. Método para diagnosticar el cáncer que comprende la medición de las células precursoras de CTL específicos de WT1
DE602005020121D1 (de) * 2004-03-31 2010-05-06 Int Inst Cancer Immunology Inc Aus wt1 stammende krebsantigenpeptide
CA2900087C (en) 2005-10-17 2024-02-13 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
CN101336249A (zh) * 2005-11-30 2008-12-31 株式会社癌免疫研究所 新型肽化合物
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
EP2857508A3 (en) 2007-03-05 2015-04-15 International Institute of Cancer Immunology, Inc. Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
WO2011130249A2 (en) * 2010-04-13 2011-10-20 Immunovative Therapies, Ltd. Methods and compositions for inhibition of treg cells
JP5646263B2 (ja) 2010-09-27 2014-12-24 任天堂株式会社 画像処理プログラム、画像処理装置、画像処理システム、および、画像処理方法
CN107238706A (zh) 2011-06-28 2017-10-10 株式会社癌免疫研究所 肽癌抗原‑特异性t细胞的受体基因
WO2013106834A2 (en) 2012-01-13 2013-07-18 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6122018A (ja) * 1984-07-06 1986-01-30 Green Cross Corp:The 癌免疫療法増強剤
WO1996002555A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
WO1999044634A1 (en) * 1998-03-05 1999-09-10 The Medical College Of Ohio Il-12 stimulation of neonatal immunity
WO2000018795A2 (en) * 1998-09-30 2000-04-06 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
WO2000041463A2 (en) * 1999-01-12 2000-07-20 Smithkline Beecham Biologicals S.A. Combination of hepatitis b vaccine with antiviral agents
WO2000044349A1 (en) * 1999-01-27 2000-08-03 Idea Ag Non-invasive vaccination through the skin
JP2001089389A (ja) * 1999-07-22 2001-04-03 Sumitomo Pharmaceut Co Ltd 抗原特異的ｔ細胞の誘導剤
WO2001062920A2 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
WO2002079253A1 (fr) * 2001-03-22 2002-10-10 Haruo Sugiyama Peptide modifie wt1

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
JPH04501663A (ja) * 1988-09-23 1992-03-26 ユニバーシティ・オブ・サザン・カリフォルニア 黒色腫用免疫療法ワクチン
ZA934890B (en) * 1992-07-08 1994-04-14 Schering Corp Use of Gm-CSF as a vaccine adjuvant
EP0984790A1 (en) * 1997-06-02 2000-03-15 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
IT246029Y1 (it) * 1998-02-26 2002-03-26 Pool S R L Apparecchio telefonico ricetrasmittente del tipo a rete mobile
JP4447779B2 (ja) * 1998-07-16 2010-04-07 市郎 東 細菌の菌体成分を有効成分とする癌免疫療法用製剤
CN1178956C (zh) * 1998-07-31 2004-12-08 杉山治夫 基于癌抑制基因wt1的产物的癌抗原
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
WO2001049317A2 (en) * 2000-01-05 2001-07-12 Aventis Pasteur Limited Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen
EP1447091A4 (en) * 2001-09-28 2008-02-13 Institute Of Can International NEW METHOD FOR INDUCTION OF ANTIGEN SPECIFIC T CELLS

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6122018A (ja) * 1984-07-06 1986-01-30 Green Cross Corp:The 癌免疫療法増強剤
WO1996002555A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
WO1999044634A1 (en) * 1998-03-05 1999-09-10 The Medical College Of Ohio Il-12 stimulation of neonatal immunity
WO2000018795A2 (en) * 1998-09-30 2000-04-06 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
WO2000041463A2 (en) * 1999-01-12 2000-07-20 Smithkline Beecham Biologicals S.A. Combination of hepatitis b vaccine with antiviral agents
WO2000044349A1 (en) * 1999-01-27 2000-08-03 Idea Ag Non-invasive vaccination through the skin
JP2001089389A (ja) * 1999-07-22 2001-04-03 Sumitomo Pharmaceut Co Ltd 抗原特異的ｔ細胞の誘導剤
WO2001062920A2 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
WO2002079253A1 (fr) * 2001-03-22 2002-10-10 Haruo Sugiyama Peptide modifie wt1

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CANCER IMMUNOL. IMMUNOTHER., vol. 51, no. 11-12, December 2002 (2002-12-01), pages 614 - 620, XP002961732 *
DATABASE CAPLUS [online] TSUBOI A. ET AL: "Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.", XP003016309, Database accession no. (2002:880632) *
HARUO SUGIYAMA: "Saibo shuki to gan - WT1 tanpaku o hyoteki ni shita gan no men'eki ryoho -", BIOTHERAPY, vol. 14, no. 8, 2000, pages 789 - 795, XP002963476 *
ICHIRO HIGASHI: "BRM to shite no saikin kintai seibun", BIOMEDICINE & THERAPEUTICS, vol. 20, no. 1, 1988, pages 21 - 26, XP002963480 *
LIN R. ET AL.: "Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases", CLIN. INFECT. DIS., vol. 21, no. 6, December 1995 (1995-12-01), pages 1439 - 1449, XP000576631 *
OKA Y. ET AL.: "Cancer immunotherapy targeting Wilms' tumor gene WT1 product", J. IMMUNOL., vol. 164, no. 4, 15 February 2000 (2000-02-15), pages 1873 - 1880, XP000890067 *
See also references of EP1447092A4 *
SUGIYAMA H. ET AL.: "Wilms' tumor gene WT1: its oncogenic function and clinical application", INT. J. HEMATOL., vol. 73, February 2001 (2001-02-01), pages 177 - 187, XP002963478 *
YOSHIHIRO OKA ET AL.: "3. Men'eki ryoho 2) WT1 o hyoteki to shita hakketsubyo ni taisuru tokuiteki men'eki ryoho", HEMATOLOGY FRONTIER, vol. 10, no. 8, 2000, pages 1017 - 1023, XP002963477 *
YOSHIRO TANIO ET AL.: "Men'eki kyoka busshitsu", JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY, vol. 7, no. 9, 1980, pages 1710 - 1718, XP002963479 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1371664A4 (en) * 2001-03-22 2006-03-22 Haruo Sugiyama WTI-MODIFIED PEPTIDE
US8105604B2 (en) 2001-03-22 2012-01-31 International Institute Of Cancer Immunology, Inc. WT1 modified peptide
EP1371664A1 (en) * 2001-03-22 2003-12-17 Haruo Sugiyama Wti modified peptide
WO2004026897A1 (ja) 2002-09-20 2004-04-01 Chugai Seiyaku Kabushiki Kaisha Ｗｔ１置換型ペプチド
US7378384B2 (en) 2002-09-20 2008-05-27 International Institute Of Cancer Immunology, Inc. WT1 substitution peptides
KR101522079B1 (ko) * 2003-11-05 2015-05-21 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 유래의 ｈｌａ-ｄｒ 결합성 항원 펩티드
US11027003B2 (en) 2003-11-05 2021-06-08 International Institute Of Cancer Immunology, Inc. HLA-DR-binding antigen peptide derived from WT1
EP1696027A1 (en) * 2003-11-05 2006-08-30 International Institute of Cancer Immunology, Inc. Hla-dr-binding antigen peptide derived from wt1
US10124046B2 (en) 2003-11-05 2018-11-13 International Institute Of Cancer Immunology, Inc. HLA-DR-binding antigen peptide derived from WT1
EP1696027A4 (en) * 2003-11-05 2008-05-14 Int Inst Cancer Immunology Inc ANTIGEN PEPTIDE BINDING TO ORIGINAL HLA-DR WT1
EP2071028A3 (en) * 2003-11-05 2009-06-24 International Institute of Cancer Immunology, Inc. HLA-DR-binding antigen peptide derived from WT1
JP5041279B2 (ja) * 2004-04-22 2012-10-03 株式会社 Ｍｂｒ 細菌細胞壁骨格成分を含有する製剤
JPWO2005102369A1 (ja) * 2004-04-22 2008-03-06 大日本住友製薬株式会社 細菌細胞壁骨格成分を含有する製剤
WO2005102369A1 (ja) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. 細菌細胞壁骨格成分を含有する製剤
US10139395B2 (en) 2007-02-27 2018-11-27 International Institute Of Cancer Immunology, Inc. Method for activation of helper T cell and composition for use in the method
US11555814B2 (en) 2007-02-27 2023-01-17 International Institute Of Cancer Immunology, Inc. Method for activation of helper t cell and composition for use in the method
US10654892B2 (en) 2010-10-05 2020-05-19 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
US9833493B2 (en) 2012-12-17 2017-12-05 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
WO2018219299A1 (en) * 2017-05-31 2018-12-06 Carsgen Therapeutics Co., Ltd. Compositions and methods of cellular immunotherapy
US11419895B2 (en) 2017-05-31 2022-08-23 Crage Medical Co., Limited Compositions and methods of cellular immunotherapy

Also Published As

Publication number Publication date
EP1447092A4 (en) 2007-07-11
JPWO2003028758A1 (ja) 2005-01-13
US20050002951A1 (en) 2005-01-06
EP1447092A1 (en) 2004-08-18
JP2010215653A (ja) 2010-09-30

Similar Documents

Publication Publication Date Title
WO2003028758A1 (fr) Nouvelle methode d'induction de lymphocytes t specifiques d'un antigene
WO2003028757A1 (fr) Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
DE60229979D1 (ja)
WO2003059276A3 (en) Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
WO2003002136A3 (en) Stable formulation of modified glp-1
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
AU3121497A (en) Methods of treating type i hypersensitivity using monophosphoryl lipid
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
MXPA05007211A (es) Composicion farmaceutica que comprende una region de fc de inmunoglobulina como un vehiculo.
AU7315496A (en) Delivery of biologically active polypeptides
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL142905A0 (en) Functional antagonists of hedgehog activity
NO20060955L (no) Farmasoytisk sammensetning som er nyttig til stamcellemobilisering
AU2002231654A1 (en) Pharmaceutical paste comprising an acid-labile active ingredient
WO2002088328A3 (en) Method for generating highly active human dendritic cells from monocytes
AU2084801A (en) Antiviral medication
WO2000054730A3 (en) Compositions preparations and uses of human papillomavirus l1 protein
EP2502998A3 (en) Recombinant toxin A/ToxinB vaccine against clostridium difficile
EP2292255A3 (de) Stabile therapeutische Proteine
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
MXPA04003526A (es) Composicion y metodo para el tratamiento de la diabetes.
AR034749A1 (es) Formulaciones de interferon beta humano
AU1041397A (en) Antigenic protein originating in malassezia
ATE395064T1 (de) Kombinationspräparate von 3-n- formylhydroxylaminopropylphosphonsäurederivaten oder 3-n- acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
EP1583545A4 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF PEPTIDES OF HIV GP41 AND ITS THERAPEUTIC USE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003532088

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002800255

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10490865

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002800255

Country of ref document: EP